Explore probiotics for a balanced gut microbiome

Several clinically studied probiotic strains have demonstrated strain-specific evidence for gastrointestinal applications, including Pediococcus acidilactici KABP® 021, Lactiplantibacillus plantarum KABP® 022, Bifidobacterium longum KABP® 042, Pediococcus pentosaceus KABP® 041, Lactobacillus rhamnosus GG, and Weizmannia (Bacillus) coagulans (Unique IS2®). Each strain has a defined mechanism of action, from gut barrier support and digestive comfort to microbiota restoration, rather than a generic “gut health” positioning.

For brands building in this category, strain-level clinical validation is the foundation of credible product claims and regulatory substantiation. Kaneka Probiotics’ KABP® Intensive G.I. is backed by eight clinical studies, and KABP® Digest by seven — among the most clinically substantiated GI formulations available to brands today.

Single-strain probiotics deliver a targeted mechanism of action tied to one well-characterized strain, which is the right choice when precise claims and maximum formulation stability are the priority. Multi-strain probiotics combine two or more clinically selected strains to address multiple gut health pathways simultaneously.

Combining strains only adds value when each strain contributes a complementary mechanism, not a redundant one. Intentional formulation is what separates a differentiated multi-strain product from a commodity blend. KABP® Intensive G.I., for example, pairs P. acidilactici KABP® 021, L. plantarum KABP® 022, and L. plantarum KABP® 023 to support gut barrier function, digestive comfort, and microbiota balance within a single formulation, with each strain contributing a defined role. The right approach depends on your product’s target indication, desired claims, and clinical substantiation requirements.

Gut dysbiosis is an imbalance in the gut’s microbial community — a disruption to the diversity, composition, or functional capacity of the microorganisms that make up the gut microbiome. Research suggests that dysbiosis may contribute to a range of gastrointestinal symptoms, including occasional digestive discomfort and irregularity.

For brands developing GI health products, dysbiosis represents both the underlying mechanism your formulation needs to address and the primary driver of consumer demand in this category. Probiotic solutions designed to restore microbiota balance, support gut barrier integrity, and promote homeostasis are directly aligned with this opportunity, provided the strains included are clinically validated for those specific outcomes, not just broadly positioned for digestive wellness.

Antibiotic-associated diarrhea (AAD) is one of the most clinically well-supported probiotic applications, but it requires strain-specific evidence. Strains with research in this area include Lactobacillus rhamnosus GG, Bifidobacterium longum KABP® 042, and Pediococcus pentosaceus KABP® 041.

These three strains form the basis of KABP® Digest, a multi-strain formulation with 7 clinical studies supporting its indications for AAD, occasional constipation, and microbiota restoration in both adults and children.